British American Tobacco (BTI): Smokeless Growth Meets Value
British American Tobacco is a Buy for investors seeking cash generation, income, and smokeless nicotine growth. New Category momentum is improving, but leverage and combustible volume declines remain key risks.
British American Tobacco (BTI) looks like a good investment right now, earning an overall grade of B+ and a Buy. The stock offers a compelling mix of cash generation, income, and smokeless nicotine growth, and our fair value is $62.
Thesis
Investment thesis: British American Tobacco (BTI) is a Buy for moderate-risk investors seeking a medium-term combination of cash generation, income, and exposure to smokeless nicotine growth. The business produced $25.8B of trailing revenue, $11.2B of EBITDA, a 25.0% net margin, and a 5.7% free-cash-flow yield. Its valuation is restrained at 14.5x trailing earnings, 10.7x forward earnings, and a 1.4 PEG ratio.
The central attraction is the transition from cigarettes toward Modern Oral, Vapour, and Heated Products. New Category revenue rose 18.0% in H1 2026, Modern Oral revenue increased 66%, and smokeless products reached 19.8% of group revenue. Velo and Vuse are providing the strongest evidence that BTI can convert its distribution scale into share gains.
The trade-off is a heavily indebted balance sheet, declining combustible volumes, uneven regional performance, and a weak recent earnings beat record of 2 beats in 8 reported quarters. BTI is not a clean growth stock. It is a cash-generative transition company whose valuation leaves room for execution, but not for complacency.
Company Overview
Founded in 1902 and headquartered in London, British American Tobacco (BTI) operates across the United States, Europe, Latin America, Canada, Asia-Pacific, the Middle East, Central Asia, the Caucasus, and Africa. The company employed 47,797 people and traded on the NYSE under the ticker BTI.
BTI sells cigarettes, fine-cut tobacco, traditional oral tobacco, Vapour products, Heated Products, and Modern Oral nicotine pouches. Its major brands include Vuse, glo, Velo, Newport, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Natural American Spirit, Camel Snus, Grizzly, and Kodiak.
The business model has two engines. Combustibles remain the large cash generator, using pricing and brand equity to offset volume decline. New Categories absorb investment today and provide the route toward BTI's stated ambition of becoming a predominantly smokeless business by 2035.
▌Common Questions
Frequently asked questions
+Is BTI stock a buy right now?
Yes, BTI is a Buy for moderate-risk investors who want income, cash flow, and exposure to smokeless nicotine growth. The stock earns an overall grade of B+ because New Category momentum is improving while valuation remains reasonable, even though leverage and combustible declines still matter.
+What is BTI's fair value?
BTI's fair value is $62. We arrive at that view using the report's valuation picture of 14.5x trailing earnings, 10.7x forward earnings, and a 1.4 PEG ratio, while giving credit to the 18.0% H1 New Category revenue growth and the 66% surge in Modern Oral.
+
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
The February 13, 2026 20-F identifies regulation, illicit trade, litigation, foreign exchange, taxation, and execution of the New Categories strategy as material business risks. Those risks are not side notes. They are the price of admission in a heavily regulated industry.
Business Segment Deep Dive
The 2025 segment extract lists Combustibles revenue of $20.2B, equal to 91.9% of the reported segment total of $22.0B. Traditional Oral contributed $1.0B, while Others contributed $745M. This category view confirms that combustible products still dominate the economic base even as management reports a broader smokeless share of 19.8% of group revenue in H1 2026.
New Categories are gaining economic weight. H1 2026 New Category revenue increased 18.0%, category contribution rose 55% to £269M, and gross profit increased by more than £120M. Modern Oral led with 66% revenue growth, Vapour revenue grew 5.3%, and Heated Products revenue declined nearly 12%.
Combustibles remain resilient rather than healthy in volume terms. H1 combustible volume declined 4.7%, but revenue increased 2.1% because price and mix rose 6.8%. That spread shows why the legacy business can continue funding transformation, while also showing why the model depends on disciplined pricing.
Regional performance was uneven. U.S. revenue rose 8.5% and adjusted operating profit increased 10.1%. AME revenue grew 0.9% and adjusted operating profit increased 1.1%. APMEA revenue declined 6.3% and adjusted profit fell 16.5%, reflecting regulatory pressure, illicit volume, and market-specific weakness.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Velo is BTI's most important growth product. In the United States, Velo helped lift Modern Oral volume share to 31% and value share to nearly 26%. Management reported that Velo captured around 90% of category value growth, while global shipments reached 7.9B pouches in H1.
Velo's position is broader than a single U.S. launch. Across BTI's top markets, Modern Oral volume share rose more than 8 percentage points to 39%. In AME, BTI held 62% volume share across top markets and 68.5% value share, supported by brand equity scores 40% higher than the closest competitor in Europe.
Vuse remains the leading Vapour platform in the United States. Its value share reached 55.9% in H1 2026, more than double the share of its nearest competitor according to management. Vuse returned to double-digit volume and revenue growth in the U.S., although illegal single-use products continue to pressure the legal market.
glo is the weaker flagship. H1 Heated Products revenue declined nearly 12% because of inventory movements and value-segment competition. The glo Hilo platform adds dual-heating technology, a screen, customized heating modes, and a no-cleaning design, but the product still needs wider scale to offset the pressure on the existing category.
Innovation & Competitive Advantage
BTI's advantage comes from combining product breadth with distribution and regulatory capability. Velo serves Modern Oral, Vuse serves Vapour, glo serves Heated Products, and the combustible portfolio supplies the cash to finance those launches. Few global nicotine companies operate across all four formats at comparable scale.
The product pipeline is concrete. Velo Max adds two strengths and four flavors in the U.S. Vuse adult-focused flavors begin a phased rollout across approximately 25,000 outlets in Q3 2026, followed by another 25,000 outlets in Q4. Hyper Pro+ is also scheduled to strengthen glo's value proposition.
Regulatory capability is part of the moat. Thirty-two markets had adopted Modern Oral regulation by H1 2026, more than double the number in 2024. In the U.S., approximately half of Vapour industry volume was covered by state directory and enforcement frameworks, while more than 18M unauthorized Vapour products had been seized through federal cooperation.
The moat has limits. Velo and Vuse still face strong competition, and glo's revenue declined despite new hardware. BTI's advantage is therefore execution-based rather than permanent: brand, shelf space, compliance, and scale must keep producing better economics than smaller challengers.
Operations & Supply Chain
BTI distributes through retail outlets across a broad international footprint. Its 47,797 employees, global manufacturing base, and Reynolds distribution network give the company reach that smaller nicotine brands cannot easily duplicate. H1 shipment volume of 7.9B Modern Oral pouches shows the operational scale behind Velo's expansion.
The company is also reshaping its production base. Fit2Win is designed to create a leaner and more data-driven organization. BTI expects £700M of annualized savings by 2028, with £500M delivered by 2027, while a manufacturing asset review identified opportunities to install more efficient machinery.
Supply chain execution is closely tied to regulation. BTI is rolling out Vuse flavors through retailers that commit to age-verification controls, including ID scanning. That approach slows distribution compared with illicit sellers, but it supports compliance and protects the value of regulated brands.
Inventory movements also affect reported performance. U.S. combustible revenue benefited from positive trade inventory movements in H1, and management expects that benefit to reverse in H2. The company has already signaled that U.S. growth will moderate as the comparison becomes more demanding and investment increases.
Market Analysis
BTI operates in a large but mature nicotine market. Its investor presentation frames 2025 nicotine industry revenue at £100B, including £32B from New Categories and £68B from combustibles. By 2030, the presentation projects £110B of nicotine revenue, £47B of New Category revenue, and £63B of combustible revenue.
The mix shift matters more than the total market size. BTI's presentation assigns a 13% 2025 to 2030 CAGR to Heated Products and Nicotine Pouches, compared with 1.5% for Vapour. Combustible volume is expected to decline 3% to 4%, while price and mix support 1% to 2% revenue growth.
The United States is the most valuable battleground. BTI estimates the 2025 U.S. nicotine revenue pool at £42B, consisting of £27B of combustibles, £10B of Vapour, and £5B of Oral products. U.S. nicotine industry volume rose from 383 in 2023 to 434 in 2025 in the company's presentation.
BTI's near-term market opportunity is the conversion of existing nicotine consumers rather than the creation of an entirely new category. The company reported that 65% of U.S. nicotine consumers had interacted with or migrated to New Categories, up 19 percentage points from 2022. That creates room for Velo, Vuse, and glo to compete for share even as cigarette volumes contract.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
BTI serves adult nicotine consumers who differ by format, price point, geography, and regulatory environment. Combustible users remain important to cash flow, while Modern Oral users provide the strongest growth profile. BTI reported 35M smokeless consumers after adding 4.1M over the prior 12 months.
The U.S. customer base is increasingly multi-category. BTI reported that 53% of U.S. combustible consumers were poly-users, up 7 percentage points from 2022. This behavior gives BTI an opportunity to retain consumers within its portfolio, but it also means each category competes for the same nicotine budget.
Velo's customer economics show the benefit of product-market fit. The investor presentation reported that the Velo Plus consumer base grew from 2.5M to 5M, while volume rose 290% in FY2025. Velo Max expands the range with higher moisture, additional strengths, and additional flavors.
Price sensitivity remains a meaningful customer factor. The U.S. cigarette market has seen growth in the deep-discount segment, and BTI reported a 40-basis-point decline in combustible value share and an 80-basis-point decline in volume share. BTI is responding with Lucky Strike, Pall Mall Select, Doral, Newport, and Camel investments across different price tiers.
Competitive Landscape
The main global competitors are Philip Morris International (PMI), Altria (MO), and Imperial Brands (IMB). Turning Point Brands (TPB) and other regional nicotine companies add pressure in Modern Oral and traditional oral products. Competition spans cigarettes, heated tobacco, Vapour, nicotine pouches, and retail distribution.
PMI is the benchmark for smoke-free transformation, particularly through its IQOS heated-tobacco platform. MO is a major U.S. competitor in cigarettes and oral nicotine. IMB is smaller and more focused, while TPB competes directly with BTI's Modern Oral brands in the U.S.
BTI's strongest competitive evidence is category-specific. Vuse held 55.9% U.S. Vapour value share, Velo held 31% U.S. Modern Oral volume share, and BTI held 62% Modern Oral volume share across leading AME markets. Those positions give BTI the shelf access and data scale to launch new products efficiently.
The weakest position is Heated Products. glo revenue fell nearly 12% in H1 2026, and management cited heightened competition in the value segment. PMI's stronger heated-tobacco position means BTI must rely on glo Hilo, Hyper Pro+, and selective capital allocation rather than broad spending.
Macro & Geopolitical Landscape
Tobacco taxation, product regulation, and enforcement are the largest external forces affecting BTI. In the U.S., FDA prioritization guidance and action against unauthorized Vapour products supported a return to legal Vapour market growth in H1 2026. The same regulatory system can also delay launches, limit flavors, or raise compliance costs.
Illicit trade remains a direct financial issue. BTI linked APMEA weakness to illicit volume in Bangladesh and Australia, while U.S. performance benefited from enforcement actions against unauthorized Vapour products. Legal manufacturers gain when enforcement improves, but their growth remains exposed when consumers shift toward untaxed products.
Foreign exchange is another headwind. BTI expects approximately a 1% transactional FX impact on 2026 results. The company also expects an underlying tax rate of 24% to 25% and net finance costs of approximately £1.65B, so currency, tax, and interest costs remain important to earnings conversion.
Geographic complexity adds further risk. BTI cited exits from Cuba and Mozambique in its combustible performance, while the 2025 20-F identifies discontinued Russian and Belarusian businesses and the Ukraine conflict among its filing items. These exposures reinforce the value of BTI's geographic diversification, but they also make reported results more volatile.
Balance Sheet Health
▌Premium Members Only
BTI’s balance sheet earns a B- as heavy debt remains the main constraint even with strong cash generation and a 5.7% free-cash-flow yield.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
British American Tobacco (BTI) is moving in the right direction, but it is not finished. H1 2026 showed the transformation gaining traction: New Category revenue rose 18.0%, Modern Oral revenue rose 66%, smokeless products reached 19.8% of group revenue, and adjusted diluted EPS increased 7.9%.
The investment case rests on BTI converting those category gains into durable cash flow while using the combustible business to finance the shift. Velo is the clearest proof of concept, Vuse adds a valuable U.S. platform, and Fit2Win provides an internal margin lever. The balance sheet, regulation, and uneven glo and APMEA performance prevent a stronger rating.
For a medium-term, moderate-risk portfolio, BTI offers a credible Buy profile at disciplined prices. The company has enough cash generation and brand strength to remain relevant, while the smokeless transition provides a path beyond the shrinking cigarette market.
Why does British American Tobacco have a Buy rating?
BTI has a Buy rating because the business is still highly cash generative, with $25.8B of trailing revenue, $11.2B of EBITDA, and a 5.7% free-cash-flow yield. The report also highlights strong smokeless momentum, especially Velo and Vuse, which helps offset the decline in combustible volumes.
+What are the biggest risks for BTI stock?
The biggest risks are the heavily indebted balance sheet, declining combustible volumes, and uneven regional performance. The report also notes a weak recent earnings beat record of just 2 beats in 8 reported quarters, so execution has to improve for the thesis to work.
+Which products are driving BTI's growth?
Velo and Vuse are the key growth engines. Velo helped lift U.S. Modern Oral volume share to 31% and value share to nearly 26%, while Vuse reached 55.9% value share in U.S. Vapour and returned to double-digit volume and revenue growth.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.